Scandinavian ChemoTech Animal Care unit installs its first commercial installation at Evidensia
Vetiqure AB installs the vetIQure™ system at Evidensia Specialist Horse Hospital in Strömsholm with a rental agreement that can generate income of at least EUR 15,000/year.
Chief veterinarian Elin Skärlina has, during an evaluation program, treated a number of patients with Tumour-Specific Electroporation, TSE, and has now also received extended training in connection with the treatment of a horse with over 30 melanomas on its body.
Melanomas are skin tumours that in horses are also called mold nodules because they are significantly more common on greys (a name for a horse that has predominantly white or grey guard hair and dark skin, eyes and hooves). In the past, the general recommendation has been to do nothing about melanomas because they usually develop slowly and in many horses, they never cause clinical problems. This approach has now changed because in individual horses the melanoma can cause significant problems.
"We are very happy to be able to do the first permanent installation of the vetIQure system at one of Evidensia's clinics. With RVC and now the addition of Elin and her team's enormous expertise to our global network of TSE users, the conditions for giving TSE a given place in the fight against cancer and sarcoids are further strengthened. It is becoming increasingly clear that horses play a significant role in our veterinary medicine strategy in both Europe, the USA and the Middle East.” - says Mohan Frick, CEO of ChemoTech and Vetiqure.
"After an evaluation period that lasted for just over 6 months, it feels good to be able to offer the TSE treatment to our patients as an additional treatment option." - says Elin Skärlina, Chief veterinarian at Evidensia Specialist Horse Hospital Strömsholm.
About Evidensia Specialist Horse Hospital Strömsholm
One of the country's few 24-hour equine hospitals, a state-of-the-art centre for advanced medical, orthopaedic and surgical treatment of horses. Horses from all over Sweden come here to receive specialist care.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB, Phone: +46 (0)8 - 121 576 90
E-mail: certifiedadviser@redeye.se
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2023-05-05 15:10 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
